title: Role of stereotactic body radiation therapy and proton/carbon nuclei therapies.
abstract: Locally advanced non-small cell lung cancer is a disease typified by poor clinical outcomes. Patients treated with definitive radiation or chemoradiation have high rates of local tumor progression and distant metastasis. Tumor dose escalation using conventionally fractionated radiation is limited by toxicity to adjacent normal tissues. Novel treatment modalities such as stereotactic body radiation therapy or charged particle therapies potentially represent methods to dose escalate without increasing the risk of normal tissue toxicity. Here, we review the technologies of stereotactic body radiation therapy and charged particles, the reported clinical success with these modalities, and potential implementation into treatment regimens for locally advanced non-small cell lung cancer.
authors.affiliation: Department of Radiation Oncology, The Ohio State University, Columbus, OH 43210, USA. terence.williams@osumc.edu
authors.forename: Terence M
authors.initials: TM
authors.lastname: Williams
authors.forename: Adam
authors.initials: A
authors.lastname: Maier
mesh_terms: D002250:Carbon Radioisotopes / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D019583:Dose Fractionation, Radiation; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery*; D009367:Neoplasm Staging; D061766:Proton Therapy; D011836:Radiation Tolerance; D016634:Radiosurgery; D011882:Radiotherapy, High-Energy
chemical_list: D002250:Carbon Radioisotopes